Rebecca Tollervey - October 28, 2024 Claim Requests found Inadmissible in EPO Appeal Proceedings: What Can Proprietors Do? Since the EPO’s Rule of Procedure of the Boards of Appeal (RPBA) were revised in 2020, parties have ...
Rebecca Tollervey - July 16, 2024 EPO case law for antibodies – 2024 update In 2023 we published a pair of articles reviewing EPO case law in the field of antibodies, ...
Rebecca Tollervey - May 9, 2023 Patenting antibodies – the latest developments from the EPO Boards of Appeal: Part 2 – inventive step We have conducted a review of Board of Appeal decisions relating to antibody patents published ...
Rebecca Tollervey - February 1, 2023 Patenting antibodies – the latest developments from the EPO Boards of Appeal The prosecution of patent applications relating to antibodies involves particular considerations. ...
Rebecca Tollervey - September 8, 2021 The other end of the antibody: Fc modifications as a focus for patent protection For us antibody nerds, a fascinating aspect of the development of monoclonal antibodies against ...
Rebecca Tollervey - March 2, 2021 Patenting highly engineered antibodies in Europe In recent years, antibody engineering has moved into a new phase of complexity, with a ...
Rebecca Tollervey - October 30, 2020 Highly-engineered antibodies: evolving the patent strategy In recent years, antibody engineering has moved into a new phase of complexity, with a ...
Rebecca Tollervey - June 25, 2020 Cellular immunity – a contributor to COVID-19 “dark matter”? Immunologist Karl Friston of University College London has theorized that there may be ...
Rebecca Tollervey - November 11, 2019 Top tips for patenting antibodies in Europe Antibody development is a mature field of technology. There are relatively few new targets, and the ...
